Cargando…

A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma

There are no reports of blood triglyceride (TG) levels increasing with the ABVD regimen. Herein, we present a case of Hodgkin's lymphoma that exhibited ABVD-induced blood TG increase. The patient was a 40-year-old Japanese man. Empiric therapy was initiated using the ABVD regimen for Hodgkin ly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yonezawa, Ryo, Shimamoto, Kazushi, Kabasawa, Nobuyuki, Sano, Mizuki, Tanaka, Shizuko, Matsui, Mitsuki, Harada, Hiroshi, Sunaga, Tomiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023944/ https://www.ncbi.nlm.nih.gov/pubmed/36941843 http://dx.doi.org/10.1016/j.lrr.2023.100365

Ejemplares similares

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
por: Vakkalanka, Bhanu, et al.
Publicado: (2011)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
por: Binder, Adam F., et al.
Publicado: (2017)

Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma
por: Bond, David A., et al.
Publicado: (2019)

Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study
por: Makiyama, Junya, et al.
Publicado: (2020)

The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
por: Tamma, Roberto, et al.
Publicado: (2023)

T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
por: Entrop, Joshua P., et al.
Publicado: (2022)

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
por: Vukovic, Vojin, et al.
Publicado: (2023)

ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma
por: Amin, M. S. A., et al.
Publicado: (2020)

Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling
por: Honoré, Bent, et al.
Publicado: (2022)

Bladder Carcinoma after ABVD Chemotherapy for Hodgkin's Lymphoma: A Case Report
por: Gangopadhyay, Aparna, et al.
Publicado: (2012)

Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report
por: Subbiah, Vivek, et al.
Publicado: (2007)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
por: Schwenkglenks, Matthias, et al.
Publicado: (2010)

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma
por: Porrata, L F, et al.
Publicado: (2013)

Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report
por: Cotteret, Camille, et al.
Publicado: (2020)

A case of Hodgkin’s lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD
por: Chakraborty, Rajshekhar, et al.
Publicado: (2015)

Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation
por: DeBoer, Rebecca J., et al.
Publicado: (2020)

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma
por: Hu, Min, et al.
Publicado: (2023)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
por: Mocikova, Heidi, et al.
Publicado: (2022)

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity
por: Gibb, A, et al.
Publicado: (2013)

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence
por: Seshachalam, Arun, et al.
Publicado: (2019)

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial
por: Ricardi, Umberto, et al.
Publicado: (2021)

Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD
por: Santisteban-Espejo, Antonio, et al.
Publicado: (2022)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials
por: André, Marc P. E., et al.
Publicado: (2020)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
por: Gunther, Jillian R., et al.
Publicado: (2020)

Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study
por: Suwanban, Tawatchai, et al.
Publicado: (2023)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

A Case of Leg Pain After the Initial Dose of the COVID-19 Vaccine, Followed by Deep Vein Thrombosis and Pulmonary Embolism After the Second Dose
por: Nagao, Michiru, et al.
Publicado: (2023)

P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
por: Radford, John, et al.
Publicado: (2022)

Bob-1 is expressed in classic Hodgkin lymphoma
por: Abd El All, Howayda S
Publicado: (2007)

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
por: Relecom, Allan, et al.
Publicado: (2020)

MicroRNA signature in classical Hodgkin lymphoma
por: Paczkowska, Julia, et al.
Publicado: (2021)

Bone marrow involvement by classic Hodgkin lymphoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
por: Im, Soyoung, et al.
Publicado: (2022)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d6pa8pdj7627uhca15oup8ep5l